A thorny pathway of macrophage activating factor (GcMAF): from bench to bedside
Vitamin D3 Binding Protein (DBP) is a multifunctional glycoprotein whose main role is to transport vitamin D3 and its metabolites, but it also is the precursor of the macrophage activating factor (GcMAF). DBP is converted to GcMAF as a result of site-specific selective deglycosylation under the acti...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Siberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and Breeders
2019-08-01
|
| Series: | Вавиловский журнал генетики и селекции |
| Subjects: | |
| Online Access: | https://vavilov.elpub.ru/jour/article/view/2215 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832575128741871616 |
|---|---|
| author | A. A. Ostanin S. S. Kirikovich E. V. Dolgova А. S. Proskurina E. R. Chernykh S. S. Bogachev |
| author_facet | A. A. Ostanin S. S. Kirikovich E. V. Dolgova А. S. Proskurina E. R. Chernykh S. S. Bogachev |
| author_sort | A. A. Ostanin |
| collection | DOAJ |
| description | Vitamin D3 Binding Protein (DBP) is a multifunctional glycoprotein whose main role is to transport vitamin D3 and its metabolites, but it also is the precursor of the macrophage activating factor (GcMAF). DBP is converted to GcMAF as a result of site-specific selective deglycosylation under the action of β-galactosidase and sialidase, localized on activated B and T cells, respectively. GcMAF exerts its biological activity primarily as the capability of activating macrophages by enhancing their phagocytic function and producing ROS. Activation results in elevated expression of the specific macrophageal surface receptors involved in the recognition of tumor-associated antigens, as well as in the implementation of direct anticancer activity by inducing the apoptosis or necrosis of tumor cells. Increased interest in GcMAF is associated with its potential to be used in the clinic as a new antitumor drug. Besides its anti-tumor activity, GcMAF exerts a potential against a number of viral and neurodegenerative diseases associated with increased activity of N-acetylgalactosaminidase (nagalase) in the blood serum of patients. Nagalase is an enzyme that completely (rather than selectively) deglycosylates DBP so it cannot be converted to GcMAF, leading to immunodeficiency. Circulating DBP is composed of unmodified and O-glycosylated molecules with the glycosylation degree being dependent on the allelic variants of the gene encoding DBP. The role of DBP in the resistance of organism against a number of diseases is supported by the increased risk of a variety of severe illnesses (amyotrophic lateral sclerosis, colorectal cancer etc.) in patients deficient for GcMAF due to homozygosity for defective DBP alleles. In this review, we also will examine in detail the current data i) on the structure and functions of DBP, as the main precursor of GcMAF, ii) on the main mechanisms of GcMAF anticancer effect, iii) on the tumor strategy for neutralizing GcMAF activity, iv) on the results of GcMAF clinical trials in various cancers; and will discuss the available controversies regarding the positioning of GcMAF as an effective antitumor drug. |
| format | Article |
| id | doaj-art-f53d163408f04f1dad826b852e5f92e9 |
| institution | Kabale University |
| issn | 2500-3259 |
| language | English |
| publishDate | 2019-08-01 |
| publisher | Siberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and Breeders |
| record_format | Article |
| series | Вавиловский журнал генетики и селекции |
| spelling | doaj-art-f53d163408f04f1dad826b852e5f92e92025-02-01T09:58:08ZengSiberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and BreedersВавиловский журнал генетики и селекции2500-32592019-08-0123562463110.18699/VJ19.535952A thorny pathway of macrophage activating factor (GcMAF): from bench to bedsideA. A. Ostanin0S. S. Kirikovich1E. V. Dolgova2А. S. Proskurina3E. R. Chernykh4S. S. Bogachev5Institute of Fundamental and Clinical ImmunologyInstitute of Cytology and Genetics, SB RASInstitute of Cytology and Genetics, SB RASInstitute of Cytology and Genetics, SB RASInstitute of Fundamental and Clinical ImmunologyInstitute of Cytology and Genetics, SB RASVitamin D3 Binding Protein (DBP) is a multifunctional glycoprotein whose main role is to transport vitamin D3 and its metabolites, but it also is the precursor of the macrophage activating factor (GcMAF). DBP is converted to GcMAF as a result of site-specific selective deglycosylation under the action of β-galactosidase and sialidase, localized on activated B and T cells, respectively. GcMAF exerts its biological activity primarily as the capability of activating macrophages by enhancing their phagocytic function and producing ROS. Activation results in elevated expression of the specific macrophageal surface receptors involved in the recognition of tumor-associated antigens, as well as in the implementation of direct anticancer activity by inducing the apoptosis or necrosis of tumor cells. Increased interest in GcMAF is associated with its potential to be used in the clinic as a new antitumor drug. Besides its anti-tumor activity, GcMAF exerts a potential against a number of viral and neurodegenerative diseases associated with increased activity of N-acetylgalactosaminidase (nagalase) in the blood serum of patients. Nagalase is an enzyme that completely (rather than selectively) deglycosylates DBP so it cannot be converted to GcMAF, leading to immunodeficiency. Circulating DBP is composed of unmodified and O-glycosylated molecules with the glycosylation degree being dependent on the allelic variants of the gene encoding DBP. The role of DBP in the resistance of organism against a number of diseases is supported by the increased risk of a variety of severe illnesses (amyotrophic lateral sclerosis, colorectal cancer etc.) in patients deficient for GcMAF due to homozygosity for defective DBP alleles. In this review, we also will examine in detail the current data i) on the structure and functions of DBP, as the main precursor of GcMAF, ii) on the main mechanisms of GcMAF anticancer effect, iii) on the tumor strategy for neutralizing GcMAF activity, iv) on the results of GcMAF clinical trials in various cancers; and will discuss the available controversies regarding the positioning of GcMAF as an effective antitumor drug.https://vavilov.elpub.ru/jour/article/view/2215vitamin d3-binding protein (dbp)gc protein-derived macrophage activating factor (gcmaf)n-acetylgalactosamine (galnac)α-n-acetylgalactosaminidase (nagalase)anticancer therapy. |
| spellingShingle | A. A. Ostanin S. S. Kirikovich E. V. Dolgova А. S. Proskurina E. R. Chernykh S. S. Bogachev A thorny pathway of macrophage activating factor (GcMAF): from bench to bedside Вавиловский журнал генетики и селекции vitamin d3-binding protein (dbp) gc protein-derived macrophage activating factor (gcmaf) n-acetylgalactosamine (galnac) α-n-acetylgalactosaminidase (nagalase) anticancer therapy. |
| title | A thorny pathway of macrophage activating factor (GcMAF): from bench to bedside |
| title_full | A thorny pathway of macrophage activating factor (GcMAF): from bench to bedside |
| title_fullStr | A thorny pathway of macrophage activating factor (GcMAF): from bench to bedside |
| title_full_unstemmed | A thorny pathway of macrophage activating factor (GcMAF): from bench to bedside |
| title_short | A thorny pathway of macrophage activating factor (GcMAF): from bench to bedside |
| title_sort | thorny pathway of macrophage activating factor gcmaf from bench to bedside |
| topic | vitamin d3-binding protein (dbp) gc protein-derived macrophage activating factor (gcmaf) n-acetylgalactosamine (galnac) α-n-acetylgalactosaminidase (nagalase) anticancer therapy. |
| url | https://vavilov.elpub.ru/jour/article/view/2215 |
| work_keys_str_mv | AT aaostanin athornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT sskirikovich athornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT evdolgova athornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT asproskurina athornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT erchernykh athornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT ssbogachev athornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT aaostanin thornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT sskirikovich thornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT evdolgova thornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT asproskurina thornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT erchernykh thornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside AT ssbogachev thornypathwayofmacrophageactivatingfactorgcmaffrombenchtobedside |